<DOC>
	<DOCNO>NCT00430638</DOCNO>
	<brief_summary>This 16 week study examine ability olmesartan medoxomil lower blood pressure patient moderate severe high blood pressure comparison placebo . The medication test approved FDA treatment high blood pressure .</brief_summary>
	<brief_title>A Study Blood Pressure Lowering Ability Safety Olmesartan Medoxomil Stage I Stage II Hypertension</brief_title>
	<detailed_description>This study randomize equal number participant either olmesartan medoxomil base treatment placebo . The titration scheme follow : - First 3 week ( wks ) , participant - olmesartan medoxomil 20 mg placebo - Next 3 wks , participant whose blood pressure control - olmesartan medoxomil 40 mg placebo - Next 3 wks , participant whose blood pressure control - olmesartan medoxomil 40 mg/HCT 12.5 mg placebo - Final 3 wks , participant whose blood pressure control - olmesartan medoxomil 40 mg/HCT 25 mg placebo - Subjects mean BP &lt; 120/80 mmHg visit consider responder titrate next dose level . However , remain study currently assign dose study medication . - Subjects mean office SBP ≥120 mmHg mean office DBP ≥80 mmHg subsequent visit ( ) consider 'uncontrolled ' titrate next dose level accord titration scheme . - Subjects reach high dose ( ie , olmesartan medoxomil 40 mg/HCT 25 mg ) remain dose study exit Visit 8 , unless safety concern cause discontinuation treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Greater equal 18 year age . Patients mean seat systolic blood pressure ( MSSBP ) great equal 140 mmHg less equal 179 mmHg mean seat diastolic blood pressure ( MSDBP ) less equal 109 mmHg follow 3 4week singleblind placebo runin period . The difference MSSBP Visits 3 4 Visits 4 4X must less equal 10 mmHg . Patients mean daytime ( 8AM4PM ) systolic blood pressure ( SBP ) great equal 135 mmHg less equal 179 mmHg mean daytime diastolic blood pressure ( DBP ) less equal 109 mmHg measure ambulatory blood pressure monitoring device ( ABPM ) follow placebo runin period . If female , must negative serum pregnancy test screen either postmenopausal ( great equal 1 year ) , hysterectomy tubal ligation least 6 month consent childbearing potential , must practice approve measure birth control throughout study . History stroke transient ischemic attack ( TIA ) within last one year . History myocardial infarction , coronary angioplasty , coronary artery bypass graft , heart failure within past 6 month . Patients secondary hypertension etiology , renal disease , pheochromocytoma , Cushing 's syndrome . Type I diabetes . Patients Type II diabetes stable treatment , fast glucose &lt; 160 mg/dl may enroll . Patients hemodynamically significant cardiac valvular disease . Patients clinically significant cardiac conduction defect , include first , second third degree AV block , leave bundle branch block , sick sinus syndrome , atrial fibrillation , atrial flutter , accessory bypass tract , arrhythmia require medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin Receptor Blocker</keyword>
	<keyword>Calcium Channel Blocker</keyword>
	<keyword>Angiotensin Converting Enzyme Inhibitor</keyword>
	<keyword>Hydrochlorothiazide</keyword>
	<keyword>Stage I II Hypertension</keyword>
</DOC>